Multiple Valve Surgery Decisions.
Surgery involving two or three heart valves simultaneously represents one of the most complex and consequential operations in cardiac surgery. Multi-valve disease is common — 20-30% of patients referred for valve surgery have significant disease affecting more than one valve. The most common combinations are mitral and tricuspid disease (often from rheumatic heart disease or functional regurgitation), aortic and mitral disease (degenerative or rheumatic), and the combination of all three. Each additional valve procedure incrementally increases operative complexity, bypass time, and surgical risk. The decision-making for multi-valve surgery is exponentially more complex than for single-valve disease. For each valve, the surgeon must decide: repair or replace? If replace, mechanical or bioprosthetic? What approach — full sternotomy or minimally invasive? And critically, should a borderline secondary valve lesion (moderate mitral regurgitation in a patient having aortic valve replacement, for example) be addressed now or monitored? Addressing it adds risk to the current operation but avoids a potential reoperation years later. Leaving it may allow progression that eventually requires another surgery. These trade-offs require the kind of nuanced, multi-specialty analysis that a Heart Team is designed to provide.
What the evidence shows.
STS National Database data shows that operative mortality increases with each additional valve procedure: isolated aortic valve replacement (AVR): 2-3%; isolated mitral valve repair: 1-2%; AVR + mitral valve repair/replacement: 5-8%; triple valve surgery: 8-12%. Long bypass times (over 180 minutes) and cross-clamp times (over 120 minutes), which are common in multi-valve operations, are independent risk factors for renal failure, stroke, and low-output syndrome. However, experienced centers with high multi-valve volumes report mortality at the lower end of these ranges. Regarding the "address it now or watch it" question: a 2020 CTSN randomized trial (the CTSN Moderate Ischemic Mitral Regurgitation trial) found that adding mitral repair to CABG in patients with moderate ischemic MR did not improve survival or reduce heart failure events compared to CABG alone at 2 years — an important finding suggesting that borderline mitral regurgitation should not always be addressed.
Current recommendations.
Current recommendations for multi-valve surgery include: (1) comprehensive preoperative imaging including transesophageal echocardiography to fully characterize all valve pathology; (2) Heart Team discussion to determine which valves require intervention and which can be safely monitored; (3) valve repair preferred over replacement whenever feasible to avoid the cumulative anticoagulation burden of multiple mechanical prostheses; (4) if replacement is required for multiple valves, a consistent prosthesis strategy (all mechanical or all bioprosthetic) simplifies anticoagulation management; (5) concomitant AF ablation (Maze procedure) should be strongly considered in multi-valve patients with atrial fibrillation, as the incremental risk is minimal compared to the benefit; (6) experienced multi-valve surgical centers with high volumes should be prioritized, as outcomes are strongly volume-dependent for these complex operations.
Why this matters for your decision.
Multi-valve surgery represents the highest-complexity, highest-stakes elective cardiac surgery. The decision about which valves to address, whether to repair or replace each one, and what prosthesis to use has implications that extend across decades. A second opinion from a Heart Team experienced in multi-valve disease ensures that the surgical plan is comprehensive, that borderline lesions are appropriately triaged, and that the patient is directed to a surgeon and center with adequate multi-valve experience.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.